CD101 inhibits the expansion of colitogenic T cells

Area of Science:

• Immunology
• Gastroenterology
• Molecular Biology

Background:

• CD101 exhibits in vitro negative-costimulatory effects, but its in vivo role, particularly in inflammatory bowel disease (IBD), is unclear.
• CD101 is present on intestinal lymphoid and myeloid cells but not on naive splenic T cells.

Purpose of the Study:

• To investigate the impact of CD101 on the course of inflammatory bowel disease (IBD) using a T-cell transfer model of chronic colitis.
• To determine the specific roles of CD101 expression on T cells and myeloid cells in regulating immune responses and disease severity.

Main Methods:

• Utilized a T-cell transfer model of chronic colitis in mice.
• Analyzed lymphocyte populations, cytokine production (IL-2, IL-17, IL-10), and gene expression (FoxP3, IL-2Rα/β) in recipient mice.
• Assessed CD101 expression on peripheral and intestinal immune cells in IBD patients.

Main Results:

• Transfer of CD101-deficient T cells exacerbated colitis, increasing IL-17 production and IL-2 receptor expression.
• CD101 expression on T cells mediated regulatory T cell (Treg) function and inhibited T-cell proliferation.
• Sustained IL-10 production required CD101 expression on both T cells and myeloid cells.
• IBD patients showed reduced CD101 on monocytes and CD4+ T cells, correlating with higher IL-17 and disease activity.

Conclusions:

• CD101 plays a critical role in suppressing colitis development and progression.
• CD101 deficiency is associated with increased IL-17 and disease severity in both mouse models and human IBD.
• CD101 represents a potential therapeutic target for inflammatory bowel disease.